Latest Ratios: P/E Ratio -17.1x · EV/EBITDA N/A · ROE -19.0%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.3B | $672M | $656M | $303M | $905M | $1.2B | $525M | $512M | $855M | $426M |
| Enterprise Value | $1.8B | $1.3B | $728M | $702M | $350M | $874M | $1.2B | $556M | $534M | $809M | $404M |
| P/E Ratio → | -17.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 107.51 | 76.48 | 113.85 | 87.50 | 29.69 | 121.40 | 37.46 | 31.40 | 29.54 | 354.43 | 10.01 |
| P/B Ratio | 2.90 | 2.20 | 1.40 | 1.31 | 0.61 | 1.56 | 2.19 | 1.09 | 0.94 | 1.65 | 0.81 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 74.56 | 123.40 | 93.57 | 34.28 | 117.19 | 36.53 | 33.24 | 30.79 | 335.46 | 9.49 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2% | 70.2% | -595.9% | -632.2% | -522.6% | -1049.8% | -153.4% | -349.5% | 68.2% | -400.2% | 30.0% |
| Operating Margin | -363.1% | -363.1% | -1425.7% | -923.7% | -789.1% | -1463.2% | -232.8% | -479.6% | -446.0% | -3733.1% | -131.4% |
| Net Profit Margin | -593.9% | -593.9% | -1490.3% | -1091.7% | -894.6% | -1325.3% | -242.4% | -537.0% | -203.5% | -3184.7% | -9.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -19.0% | -19.0% | -17.9% | -16.4% | -16.9% | -17.5% | -15.1% | -17.5% | -6.6% | -14.7% | -0.7% |
| ROA | -14.1% | -14.1% | -13.1% | -12.3% | -13.0% | -13.4% | -11.2% | -13.4% | -5.2% | -11.5% | -0.5% |
| ROIC | -8.5% | -8.5% | -11.6% | -9.5% | -11.0% | -15.3% | -10.9% | -11.1% | -11.2% | -13.8% | -7.7% |
| ROCE | -9.8% | -9.8% | -13.8% | -11.2% | -12.8% | -16.9% | -12.0% | -12.6% | -12.0% | -14.1% | -6.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.25 | 0.23 | 0.22 | 0.18 | 0.18 | 0.17 | 0.11 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | 0.12 | 0.09 | 0.09 | -0.05 | -0.05 | 0.06 | 0.04 | -0.09 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.72 | -2.72 | -4.07 | -3.56 | -4.66 | -10.18 | -5.09 | -6.85 | -42.28 | — | — |
Net cash position: cash ($161M) exceeds total debt ($128M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | 1.99 | 1.18 | 1.95 | 1.36 | 1.57 | 1.51 | 1.41 | 4.21 | 1.73 | 3.02 |
| Quick Ratio | 1.77 | 1.77 | 1.18 | 1.95 | 1.36 | 1.57 | 1.52 | 1.42 | 6.03 | 1.36 | 1.01 |
| Cash Ratio | 1.57 | 1.57 | 0.85 | 1.69 | 1.17 | 1.45 | 1.43 | 1.14 | 1.57 | 1.25 | 0.74 |
| Asset Turnover | — | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.04 | 0.03 | 0.03 | 0.00 | 0.06 |
| Inventory Turnover | 0.23 | 0.23 | — | — | — | — | — | — | — | 0.87 | 0.50 |
| Days Sales Outstanding | — | 315.51 | 1295.74 | 340.52 | 157.39 | 224.70 | 15.01 | 38.00 | 974.03 | 195.51 | 6.13 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $121M | $99M | $84M | $68M | $61M | $53M | $49M | $47M | $54M | $54M |
Regulatory and liquidity binary
Based on reported figures, Mesoblast trades at a price-to-sales ratio of 98.96, which appears significantly elevated compared to peers, suggesting that the market is pricing in substantial future optionality rather than current revenue generation, which remains highly volatile and dependent on non-recurring milestone payments.
The extreme P/S multiple indicates that investors are valuing the company as a platform play rather than a commercial entity. This valuation is highly sensitive to binary regulatory outcomes, and any further delays in FDA approval could lead to a rapid contraction in multiples as the market re-evaluates the probability of successful commercialization.
As reported in financial statements, Mesoblast's ROIC has remained consistently negative, hovering around -4.6% in recent quarters, which highlights the company's inability to generate positive returns on the capital deployed into its long-dated and capital-intensive clinical development pipeline.
The negative ROIC trend reflects the structural challenge of funding high-cost R&D without a corresponding stream of commercial revenue. Until the company can demonstrate a path to self-sustaining margins, the return on invested capital will likely remain suppressed, necessitating continued reliance on dilutive financing to maintain operations.
According to recent quarterly data, the cash conversion cycle has reached 823 days, indicating significant inefficiencies in managing working capital, which is exacerbated by the long lead times inherent in the company's proprietary cell manufacturing and clinical trial processes.
The extremely high DSO and DIO figures suggest that the company faces structural difficulties in converting its development activities into cash. This inefficiency places additional strain on the balance sheet, as the company must carry significant inventory and receivables while simultaneously funding its ongoing operating burn.
Based on the most recent quarterly filings, the current ratio of 1.99 provides a temporary liquidity cushion, yet the historical volatility in cash reserves suggests that the company's ability to withstand severe regulatory or operational stress remains highly vulnerable to external funding conditions.
While the current ratio appears adequate on the surface, the underlying cash burn rate means that this liquidity is transient. Investors should monitor the company's ability to secure non-dilutive capital, as any disruption in milestone payments could rapidly deplete these reserves and force a reliance on equity markets.
As highlighted by the company's financial structure, the P/S ratio is a commonly misapplied metric for Mesoblast, as it obscures the lumpy, non-recurring nature of milestone payments that do not reflect the underlying commercial demand for the firm's mesenchymal precursor cell platform.
Using P/S to value this business model is misleading because it fails to distinguish between stable royalty income and transactional milestone payments. Analysts should instead focus on the durability of the Japanese royalty stream and the progress of manufacturing validation as more reliable indicators of the company's intrinsic value.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MESO stock.
Mesoblast Limited's current P/E ratio is -17.1x. The historical average is 23.8x.
Mesoblast Limited's return on equity (ROE) is -19.0%. The historical average is -20.0%.
Based on historical data, Mesoblast Limited is trading at a P/E of -17.1x. Compare with industry peers and growth rates for a complete picture.
Mesoblast Limited has 70.2% gross margin and -363.1% operating margin.